|
CATAY BIOTECH INC. (688065.SS) Avaliação DCF
CN | Basic Materials | Chemicals | SHH
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Cathay Biotech Inc. (688065.SS) Bundle
Obtenha informações sobre a análise de avaliação Cathay Biotech Inc. (688065Ss) com nossa calculadora DCF de ponta! Apresentando dados em tempo real para (688065Ss), este modelo do Excel permite ajustar as previsões e suposições para determinar com precisão o valor intrínseco da Cathay Biotech Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,916.2 | 1,497.2 | 2,197.5 | 2,441.1 | 2,114.2 | 2,233.6 | 2,359.8 | 2,493.2 | 2,634.0 | 2,782.9 |
| Revenue Growth, % | 0 | -21.87 | 46.77 | 11.09 | -13.39 | 5.65 | 5.65 | 5.65 | 5.65 | 5.65 |
| EBITDA | 690.5 | 649.2 | 916.5 | 994.1 | 784.2 | 888.6 | 938.8 | 991.9 | 1,047.9 | 1,107.1 |
| EBITDA, % | 36.04 | 43.36 | 41.71 | 40.72 | 37.09 | 39.78 | 39.78 | 39.78 | 39.78 | 39.78 |
| Depreciation | 117.7 | 120.6 | 172.2 | 269.8 | 289.6 | 209.0 | 220.8 | 233.3 | 246.5 | 260.4 |
| Depreciation, % | 6.14 | 8.05 | 7.84 | 11.05 | 13.7 | 9.36 | 9.36 | 9.36 | 9.36 | 9.36 |
| EBIT | 572.8 | 528.6 | 744.3 | 724.3 | 494.6 | 679.6 | 718.0 | 758.6 | 801.5 | 846.8 |
| EBIT, % | 29.9 | 35.3 | 33.87 | 29.67 | 23.4 | 30.43 | 30.43 | 30.43 | 30.43 | 30.43 |
| Total Cash | 1,225.6 | 7,039.9 | 9,629.0 | 6,295.1 | 5,390.7 | 2,072.6 | 2,189.7 | 2,313.5 | 2,444.2 | 2,582.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 243.5 | 295.0 | 275.2 | 463.6 | 385.5 | 367.0 | 387.8 | 409.7 | 432.8 | 457.3 |
| Account Receivables, % | 12.71 | 19.7 | 12.52 | 18.99 | 18.24 | 16.43 | 16.43 | 16.43 | 16.43 | 16.43 |
| Inventories | 830.1 | 775.1 | 1,185.1 | 1,573.6 | 1,466.4 | 1,263.5 | 1,334.9 | 1,410.4 | 1,490.0 | 1,574.2 |
| Inventories, % | 43.32 | 51.77 | 53.93 | 64.46 | 69.36 | 56.57 | 56.57 | 56.57 | 56.57 | 56.57 |
| Accounts Payable | 746.9 | 353.2 | 302.3 | 1,060.1 | 1,651.9 | 884.0 | 934.0 | 986.7 | 1,042.5 | 1,101.4 |
| Accounts Payable, % | 38.98 | 23.59 | 13.75 | 43.43 | 78.14 | 39.58 | 39.58 | 39.58 | 39.58 | 39.58 |
| Capital Expenditure | -511.1 | -763.1 | -1,474.7 | -4,198.4 | -1,569.8 | -1,425.1 | -1,505.6 | -1,590.7 | -1,680.5 | -1,775.5 |
| Capital Expenditure, % | -26.67 | -50.97 | -67.11 | -171.99 | -74.25 | -63.8 | -63.8 | -63.8 | -63.8 | -63.8 |
| Tax Rate, % | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 | 18.36 |
| EBITAT | 493.5 | 464.5 | 598.2 | 575.8 | 403.8 | 564.8 | 596.7 | 630.5 | 666.1 | 703.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -226.7 | -568.1 | -1,145.5 | -3,171.8 | -99.1 | -1,197.9 | -730.2 | -771.5 | -815.1 | -861.1 |
| WACC, % | 7.24 | 7.25 | 7.23 | 7.22 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 | 7.23 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3,601.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -878 | |||||||||
| Terminal Value | -16,781 | |||||||||
| Present Terminal Value | -11,835 | |||||||||
| Enterprise Value | -15,436 | |||||||||
| Net Debt | -3,614 | |||||||||
| Equity Value | -11,822 | |||||||||
| Diluted Shares Outstanding, MM | 582 | |||||||||
| Equity Value Per Share | -20.32 |
What You Will Receive
- Customizable Excel Template: A fully adjustable Excel-based DCF Calculator featuring pre-filled financial data for Cathay Biotech Inc. (688065SS).
- Data from Real Markets: Access to historical performance data and future projections (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth rates, EBITDA percentages, and WACC.
- Instant Calculations: View real-time impacts of your inputs on the valuation of Cathay Biotech Inc. (688065SS).
- Professional-Grade Tool: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Interface: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Advanced DCF Calculator: Features comprehensive unlevered and levered DCF valuation models tailored for Cathay Biotech Inc. (688065SS).
- WACC Calculator: Equipped with a pre-structured Weighted Average Cost of Capital sheet that allows for customizable inputs relevant to the biotech industry.
- Editable Forecast Assumptions: Easily adjust growth projections, capital expenditures, and discount rates to fit Cathay Biotech Inc. (688065SS) specific circumstances.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Cathay Biotech Inc. (688065SS).
- Dashboard and Charts: Visual representations that condense essential valuation metrics for straightforward analysis of Cathay Biotech Inc. (688065SS).
How It Functions
- Download: Obtain the pre-configured Excel file containing Cathay Biotech Inc.'s (688065SS) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC as needed.
- Real-time Updates: The intrinsic value and NPV calculations refresh instantly with any changes.
- Scenario Testing: Develop various projections and compare results without delay.
- Informed Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Opt for Cathay Biotech Inc. (688065SS) Calculator?
- Time Efficient: Skip the hassle of building a DCF model from the ground up – it's ready for immediate use.
- Enhanced Accuracy: Dependable financial data and formulas minimize valuation mistakes.
- Completely Customizable: Adjust the model to reflect your unique assumptions and forecasts.
- User-Friendly: Intuitive charts and outputs simplify result interpretation.
- Endorsed by Professionals: Crafted for experts who prioritize precision and ease of use.
Who Can Benefit from Cathay Biotech Inc. (688065SS)?
- Biotechnology Students: Discover bioprocessing techniques and apply them to real-world scenarios.
- Researchers: Utilize innovative models in your studies or grant proposals.
- Investors: Evaluate your strategies and analyze the market performance of Cathay Biotech Inc. (688065SS).
- Industry Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
- Entrepreneurs: Understand how major biotech firms like Cathay Biotech Inc. (688065SS) are assessed and valued.
Contents of the Template
- Preloaded Cathay Biotech Data: Historical and projected financial metrics, including revenue, EBIT, and capital expenditures for Cathay Biotech Inc. (688065SS).
- DCF and WACC Models: Professional-grade worksheets designed for calculating the intrinsic value and Weighted Average Cost of Capital specific to Cathay Biotech Inc. (688065SS).
- Editable Inputs: Yellow-highlighted cells allow users to modify key variables such as revenue growth, tax rates, and discount rates.
- Financial Statements: Detailed annual and quarterly financial reports for in-depth analysis of Cathay Biotech Inc. (688065SS).
- Key Ratios: Performance evaluation through profitability, leverage, and efficiency ratios.
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions for Cathay Biotech Inc. (688065SS).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.